Yasushi Fujimoto

Nov 6, 2023 | bmccancer.biomedcentral.com | Tomoya Yokota |Sadamoto Zenda |Takeshi Kodaira |Naomi Kiyota |Yasushi Fujimoto |Koichiro Wasano | +7 more

Methods/designThis study is a multi-institutional, two-arm, open-label, randomized phase III study. The study protocol was reviewed by the Japan Clinical Oncology Group (JCOG) Protocol Review Committee and approved by as the JCOG1912 (NEW BRIDGE) in January 2021. The certificated review board approved in March 2021, and patient accrual was started at May 2021. The trial registry number is jRCTs031210100 (https://jrct.niph.go.jp/latest-detail/jRCTs031210100).